Brokers Issue Forecasts for NAGE Q4 Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Research analysts at HC Wainwright issued their Q4 2025 earnings per share (EPS) estimates for Niagen Bioscience in a research report issued to clients and investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $0.02 per share for the quarter. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.13 EPS.

Several other equities analysts also recently weighed in on NAGE. Canaccord Genuity Group decreased their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.28.

Niagen Bioscience Stock Performance

Shares of NAGE stock opened at $5.00 on Thursday. Niagen Bioscience has a fifty-two week low of $4.93 and a fifty-two week high of $14.69. The firm has a market capitalization of $399.05 million, a P/E ratio of 20.83 and a beta of 2.35. The stock’s fifty day moving average is $6.10 and its two-hundred day moving average is $7.52.

Hedge Funds Weigh In On Niagen Bioscience

Large investors have recently modified their holdings of the business. Precision Wealth Strategies LLC acquired a new stake in shares of Niagen Bioscience in the third quarter valued at $1,527,000. BSW Wealth Partners purchased a new position in Niagen Bioscience during the 3rd quarter valued at about $793,000. Navellier & Associates Inc. purchased a new position in Niagen Bioscience during the 3rd quarter valued at about $1,768,000. Silverberg Bernstein Capital Management LLC acquired a new position in Niagen Bioscience in the 3rd quarter valued at about $1,169,000. Finally, Hussman Strategic Advisors Inc. purchased a new stake in Niagen Bioscience during the third quarter worth about $980,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.